Travere Therapeutics, Inc.
TVTXMartin Shkreli (/ˈʃkrɛli/; born March 17, 1983) is an American investor and businessman. Shkreli is the co-founder of the hedge funds Elea Capital, MSMB Capital Management, and MSMB Healthcare, the co-founder and former CEO of pharmaceutical firms Retrophin and Turing Pharmaceuticals, and the former CEO of start-up software company Gödel Systems, which he founded in August 2016.
Drugs in Pipeline
5
Phase 3 Programs
4
Upcoming Catalysts
3
Next Catalyst
Jun 15, 2026
11wMarket Overview
Stock performance and key metrics
4 upcoming, 0 past
Irbesartan
Focal Segmental Glomerulosclerosis
Dapagliflozin
Immunoglobulin A Nephropathy
Pegtibatinase
Homocystinuria
Sparsentan
Focal Segmental Glomerulosclerosis
RE-021 (Sparsentan)
Focal Segmental Glomerulosclerosis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Irbesartan | Phase 3 | Focal Segmental Glomerulosclerosis | - | - |
Dapagliflozin | Phase 3 | Immunoglobulin A Nephropathy | - | - |
Pegtibatinase | Phase 3 | Homocystinuria | - | - |
Sparsentan | Phase 3 | Focal Segmental Glomerulosclerosis | - | - |
RE-021 (Sparsentan) | Phase 2 | Focal Segmental Glomerulosclerosis | - | - |